
An @OfficialNIHR study aimed at assessing the clinical and cost-effectiveness strategies for the management of juxtarenal abdominal aortic aneurysms
Liverpool, England
Joined December 2016
- Tweets115
- Following253
- Followers624
- Likes43
UK-COMPASS retweeted
Don't miss this #EJVESVA of the 'UK- COMPASS Study: Perioperative and Midterm Outcomes' @ComplexAAAStudy @VallabhaneniRao @Jonnyboyle1 @JoseeRijn @petarz_91 #aortaed
doi.org/10.1016/j.ejvs.2024.…
Replying to @smholder92
Sophie and Alastair: absolute pillars of the study along with Shaneel and Richard! And of course the full team!
Comparison of Open Surgery and Endovascular Techniques for Juxtarenal and Complex Neck Aortic Aneurysms: The UK COMPlex AneurySm Study (UK-COMPASS) – Perioperative and Midterm Outcomes - European J of Vascular and Endovascular Surgery ejves.com/article/S1078-5884…
UK-COMPASS mid term results e-published in EJVES. Pre-proof available on open access. Print PDF will be available soon.
Replying to @ResearchWales @davebosanquet
Congratulations! Well deserved!!
UK-COMPASS retweeted
ASPIRE 8 will be held on 23/24 March 2023 in Liverpool. Can any ST8 or equivalent Vascular Trainee please DM me if interested in attending. @VSGBI @RouleauxClub @paulmoxey @GarnhamAndy @mrdavid_russell
Replying to @profawbradbury @farazhmughal
Very soon - shall keep in touch.
Replying to @profawbradbury @farazhmughal
Thanks for engaging Andrew - a debate is very much necessary. For the record, at the study design workshop in Glasgow 2014 every FEVAR centre in the U.K. was present and not a single centre was prepared to randomise!
Replying to @profawbradbury @farazhmughal
We pointed out to the guidelines committee to note that an NIHR funded study, UK-COMPASS was in progress when making research recommendations. The committee chose to ignore that and recommended an RCT anyway.
Replying to @profawbradbury @farazhmughal
Andrew, the main reason for UK-COMPASS not being an RCT was a complete lack of equipoise - your centre was at our workshop in Glasgow 2014 unequivocally un-equipoised.
UK-COMPASS retweeted
Reflecting of very successful #VSASM2022 in #Brighton , thank you @rebellvascular and @VSGBI for the slightly less flashy bling! Also big thanks to overseas and invited lecture speakers @AWBeckMD @KevinMani7 @IanLoftus2 @FLareyre
Replying to @IanLoftus2 @doctorhammond @NICEComms @BSIR_News @VSGBI @cirsesociety @SIRspecialists @NIHRresearch
Absolutely. Absolutely. Absolutely. More analyses coming out on this question from UK-COMPASS. Also an important strand in our design of Personalised Decision Making in AAA research.
Replying to @profawbradbury @doctorhammond @NICEComms @BSIR_News @VSGBI @cirsesociety @SIRspecialists @NIHRresearch
Nothing unique. Issues are methodological, practical, feasibility in a timely manner - basic elements to consider to deliver & have impact. There is little attraction in starting a study that can’t recruit or complete a study that is then ignored. Await manuscripts.
Replying to @profawbradbury @doctorhammond @NICEComms @BSIR_News @VSGBI @cirsesociety @SIRspecialists @NIHRresearch
Reasons were presented at VSGBI. Nothing to be astonished about. Straight forward methodological issued and practicability.
UK-COMPASS retweeted
Replying to @doctorhammond @ComplexAAAStudy @NICEComms @BSIR_News @VSGBI @cirsesociety @SIRspecialists @NIHRresearch
I think we need to move away from the ‘one is better than the other’ mantra and accept these as complimentary therapies. The key surely is who benefits most from which (or conservative) treatment? Perhaps COMPASS will actually show our current selection pathways are working.
Replying to @IanLoftus2 @doctorhammond @NICEComms @BSIR_News @VSGBI @cirsesociety @SIRspecialists @NIHRresearch
Results pattern is the same as in RCTs of Open V Endo. The divergence is muted when risk adjusted but still there. Agree not the same as RCT, but no RCT was powered beyond peri-op death. Caution always necessary, but there are few surprises here.
UK-COMPASS retweeted
Replying to @ComplexAAAStudy @DevinZarkowsky @doctorhammond @NICEComms @BSIR_News @VSGBI @cirsesociety @SIRspecialists @NIHRresearch @BEST_CLI
In this case I see general agreement across studies. One treatment is safer but demonstrably less effective over time. With improvements the gap will close . The reality today in the US is rampant off IFU use even in good risk pts






